New research from CP3's Tim Anderson, published today in JAMA, finds that more than half of U.S. adults ages 30 to 79 (about 87.5 million people) are now recommended for statins under updated...
CP3 faculty Lucas Berenbrok, PharmD, MS, FAPhA, Associate Professor and Director of the University of Pittsburgh School of Pharmacy CLIP Center, and collaborator Elaine Mormer, PhD (Department of...
This week the FDA approved Lipfendra (enlicitide), a once-daily pill and the first oral PCSK9 inhibitor for high cholesterol. CP3's Dr. Tim Anderson spoke with TribLIVE on what this means for patients...
Drs. Walid Gellad and Courtney Kuza were pleased to represent CP3 at the College on Problems of Drug Dependence (CPDD) Annual Scientific Conference in Portland, OR. Both took part in a mini-symposium...
CP3 always has a good showing at the Professional Society for Health Economics and Outcomes Research (ISPOR) annual conference, and this year was no exception. Not only did our machine learning expert...
A recent article in The Incidental Economist examines new approaches to paying for high-cost gene therapies, focusing on “rev pay” models that spread payments over time rather than requiring a large...
A new STAT article highlights major shifts in CVD prevention guidelines, including considering statins as early as age 30 and using updated risk tools. CP3’s Dr. Tim Anderson, interviewed for the...
A new CIDRAP article examines practical strategies to curb inappropriate antibiotic prescribing in dental care, a persistent contributor to antimicrobial resistance and avoidable patient harm. The...
A new CIDRAP report highlights that dentists continue to prescribe millions of antibiotics each year in the U.S., often for prophylaxis or conditions where they may not be indicated, raising ongoing...
